JP5717650B2 - トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成 - Google Patents

トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成 Download PDF

Info

Publication number
JP5717650B2
JP5717650B2 JP2011543721A JP2011543721A JP5717650B2 JP 5717650 B2 JP5717650 B2 JP 5717650B2 JP 2011543721 A JP2011543721 A JP 2011543721A JP 2011543721 A JP2011543721 A JP 2011543721A JP 5717650 B2 JP5717650 B2 JP 5717650B2
Authority
JP
Japan
Prior art keywords
ethoxy
radiopharmaceutical composition
radiopharmaceutical
pet
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011543721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514007A5 (enExample
JP2012514007A (ja
Inventor
タイラー・ベネダム
ジェフ・ゴールディング
ナサニエル・リム
ジャン・ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avid Radiopharmaceuticals Inc
Original Assignee
Avid Radiopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avid Radiopharmaceuticals Inc filed Critical Avid Radiopharmaceuticals Inc
Publication of JP2012514007A publication Critical patent/JP2012514007A/ja
Publication of JP2012514007A5 publication Critical patent/JP2012514007A5/ja
Application granted granted Critical
Publication of JP5717650B2 publication Critical patent/JP5717650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011543721A 2008-12-31 2009-12-29 トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成 Active JP5717650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14188508P 2008-12-31 2008-12-31
US61/141,885 2008-12-31
PCT/US2009/069741 WO2010078370A1 (en) 2008-12-31 2009-12-29 Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof

Publications (3)

Publication Number Publication Date
JP2012514007A JP2012514007A (ja) 2012-06-21
JP2012514007A5 JP2012514007A5 (enExample) 2013-06-06
JP5717650B2 true JP5717650B2 (ja) 2015-05-13

Family

ID=42310197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543721A Active JP5717650B2 (ja) 2008-12-31 2009-12-29 トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成

Country Status (35)

Country Link
US (1) US20100172836A1 (enExample)
EP (1) EP2381967B1 (enExample)
JP (1) JP5717650B2 (enExample)
KR (1) KR20110119670A (enExample)
CN (1) CN102271716B (enExample)
AU (1) AU2009335049B2 (enExample)
BR (1) BRPI0923890A2 (enExample)
CA (1) CA2748705C (enExample)
CO (1) CO6341578A2 (enExample)
CR (1) CR20110410A (enExample)
CY (1) CY1118658T1 (enExample)
DK (1) DK2381967T3 (enExample)
DO (1) DOP2011000210A (enExample)
EA (1) EA023014B1 (enExample)
EC (1) ECSP11011242A (enExample)
ES (1) ES2620402T3 (enExample)
HN (1) HN2011001810A (enExample)
HR (1) HRP20170453T1 (enExample)
HU (1) HUE033649T2 (enExample)
IL (1) IL213674A (enExample)
LT (1) LT2381967T (enExample)
MA (1) MA33004B1 (enExample)
MX (1) MX2011007063A (enExample)
MY (1) MY162312A (enExample)
NZ (1) NZ593848A (enExample)
PE (1) PE20120007A1 (enExample)
PL (1) PL2381967T3 (enExample)
PT (1) PT2381967T (enExample)
RS (1) RS55674B1 (enExample)
SG (1) SG172439A1 (enExample)
SI (1) SI2381967T1 (enExample)
TN (1) TN2011000318A1 (enExample)
UA (1) UA105914C2 (enExample)
WO (1) WO2010078370A1 (enExample)
ZA (1) ZA201104824B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039815A1 (en) * 2008-09-30 2010-04-08 Case Western Reserve University Molecular probes for imaging of myelin
BR112012030946A2 (pt) * 2010-06-04 2016-11-01 Piramal Imaging Sa método para a produção de ligante para amiloide beta marcado com f-18
CA2801530C (en) 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
TWI504414B (zh) * 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產F-18標記之Aβ配位體之方法
WO2012145169A2 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
MY183997A (en) * 2011-06-21 2021-03-17 Life Molecular Imaging Sa Formulations of fluorinated stilbene suitable for pet imaging
CA2852840A1 (en) 2011-10-19 2013-04-25 Piramal Imaging Sa Improved method for production of f-18 labeled a.beta. ligands
CN102432529B (zh) * 2011-11-14 2014-03-26 江苏省原子医学研究所 一种苯乙烯基吡啶二硫二氮衍生物的制备方法
WO2013090497A1 (en) * 2011-12-15 2013-06-20 Ge Healthcare Limited Heterocyclic compounds as imaging probes of tau pathology
CN102526765B (zh) * 2011-12-31 2014-07-30 郑州泰基鸿诺药物科技有限公司 一种Aβ斑块显像剂及其制备方法
CN103965105A (zh) * 2013-01-29 2014-08-06 中山大学 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
WO2017014599A1 (ko) * 2015-07-22 2017-01-26 주식회사 씨코헬스케어 [18f]플루오로-도파의 방사화학적 순도를 안정화시키는 조성물 및 이의 제조방법
ES2864825T3 (es) * 2015-11-13 2021-10-14 Lilly Co Eli Derivados de azetidina para la obtención de imágenes Tau
EP3426309B1 (en) * 2016-03-09 2022-05-04 Case Western Reserve University Radioligands for myelin
CN107198780A (zh) * 2016-03-18 2017-09-26 南京江原安迪科正电子研究发展有限公司 放射性药物组合物及其制备方法、应用
CN106018575B (zh) * 2016-05-05 2018-10-19 江苏省原子医学研究所 一种PET显像剂前体TsOP-(+)-DTBZ及其光学异构体的分离测定方法
US10695450B2 (en) * 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
DK3538161T3 (da) * 2016-11-08 2022-09-05 Univ California Fremgangsmåder til flerdosissyntese af [F-18]FDDNP til kliniske indstillinger
TW201906818A (zh) * 2017-05-31 2019-02-16 美商511製藥公司 新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用
EA202091766A1 (ru) * 2018-01-24 2021-02-18 Ац Иммуне Са Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
CN111499570B (zh) * 2019-01-31 2023-05-16 中国医学科学院放射医学研究所 一种av-45中间体的合成方法
CN111499544B (zh) * 2019-01-31 2022-12-02 中国医学科学院放射医学研究所 一种一锅法制备N-Boc-N-甲基-4-氨基苯乙烯的合成方法
JP7576334B2 (ja) * 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
CN115400232A (zh) * 2021-05-26 2022-11-29 汉中汉核医疗科技有限公司 一种放射性药物合成方法
CN115403434A (zh) * 2021-05-26 2022-11-29 汉中汉核医疗科技有限公司 一种放射性药物的合成方法
CN113582885B (zh) * 2021-08-30 2023-04-21 南京克米斯璀新能源科技有限公司 一种烷基磺酸钠的生产方法
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
KR20250107902A (ko) * 2022-11-14 2025-07-14 일라이 릴리 앤드 캄파니 플로르베타피르 전구체 av-105의 다형체 형태
CN119080714A (zh) * 2024-09-12 2024-12-06 四川大学 一种偶氮苯磺酸酯化合物及其制备方法和应用、放射性探针的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525211A (ja) * 2004-01-19 2007-09-06 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド パーキンソン病の診断検査
CA2591534C (en) * 2004-12-17 2013-08-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
PL1999109T3 (pl) * 2006-03-30 2012-05-31 Univ Pennsylvania Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych

Also Published As

Publication number Publication date
MA33004B1 (fr) 2012-01-02
WO2010078370A1 (en) 2010-07-08
BRPI0923890A2 (pt) 2015-07-28
TN2011000318A1 (en) 2012-12-17
HK1162951A1 (en) 2012-09-07
HUE033649T2 (en) 2017-12-28
CN102271716A (zh) 2011-12-07
HRP20170453T1 (hr) 2017-06-02
HN2011001810A (es) 2013-08-12
UA105914C2 (uk) 2014-07-10
SI2381967T1 (sl) 2017-03-31
EA023014B1 (ru) 2016-04-29
MX2011007063A (es) 2011-12-16
DK2381967T3 (en) 2017-03-27
ES2620402T3 (es) 2017-06-28
KR20110119670A (ko) 2011-11-02
US20100172836A1 (en) 2010-07-08
CN102271716B (zh) 2014-11-19
DOP2011000210A (es) 2011-09-15
CO6341578A2 (es) 2011-11-21
MY162312A (en) 2017-05-31
CR20110410A (es) 2011-12-08
CA2748705C (en) 2017-05-02
PL2381967T3 (pl) 2017-06-30
JP2012514007A (ja) 2012-06-21
SG172439A1 (en) 2011-07-28
IL213674A0 (en) 2011-07-31
CA2748705A1 (en) 2010-07-08
AU2009335049B2 (en) 2015-07-16
PE20120007A1 (es) 2012-01-16
ECSP11011242A (es) 2011-10-31
PT2381967T (pt) 2017-02-24
EP2381967B1 (en) 2017-01-18
EP2381967A1 (en) 2011-11-02
CY1118658T1 (el) 2017-07-12
IL213674A (en) 2016-04-21
EP2381967A4 (en) 2013-01-02
ZA201104824B (en) 2013-01-30
AU2009335049A1 (en) 2011-07-21
LT2381967T (lt) 2017-04-25
EA201170911A1 (ru) 2011-12-30
RS55674B1 (sr) 2017-06-30
NZ593848A (en) 2013-09-27

Similar Documents

Publication Publication Date Title
JP2012514007A (ja) トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成
US20200222562A1 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
ES2867814T3 (es) Compuestos heterocíclicos deuterados y su uso como agentes de formación de imágenes
US20080267879A1 (en) Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders
CN103298789A (zh) 作为τ蛋白病理成像探针的杂环化合物
US20080219922A1 (en) Alzheimer's Disease Imaging Agents
Nan et al. 6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease
WO2014052454A1 (en) Imaging agents
Neumaier et al. Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
EP3835293B1 (en) Monoamine oxidase b imaging probe
HK1162951B (en) Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
AU2002350751A1 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
WO2010135493A2 (en) Alzheimer's disease imaging agents
WO2014184682A1 (en) Radiolabeled gnrh antagonists as pet imaging agents
JP2021102593A (ja) タウを画像化する新規化合物
Morais et al. Author's Accepted Manuscript
HK1170672B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
JP2012207995A (ja) 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識pet分子イメージングプローブ
HK1245645B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150317

R150 Certificate of patent or registration of utility model

Ref document number: 5717650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250